Lung Cancer

Seventy-five percent of patients diagnosed with metastatic adenocarcinoma of the lung before age 40 have an actionable mutation, according to preliminary results from the Genomics of Young Lung Cancer Study.

The incidence of NSCLC among self-reported never-smokers appears to be increasing, according to authors of two retrospective studies presented at the 2015 World Conference on Lung Cancer.

The newly revised 8th edition of the tumor, node, and metastasis (TNM) classification of lung cancer will improve the precision of staging and provide physicians with new data with which to treat patients.

The investigational agent IMMU-32 is well-tolerated in patients with previously-treated metastatic lung cancer, and interim survival data are “encouraging.”

Adding the angiogenesis inhibitor bevacizumab to standard cisplatin/pemetrexed chemotherapy prolonged survival by more than 2 months among patients with malignant pleural mesothelioma.

Postsurgical chemo-immunotherapy offers improved survival rates for patients with NSCLC, compared to adjuvant chemotherapy alone, according to a small phase III study.

Treatment with nivolumab and ipilimumab is clinically active and has a manageable safety profile for chemotherapy-naive patients diagnosed with advanced NSCLC.

Oncology teams need to spot emerging immune-related adverse events associated with immunotherapies early in order to avoid treatment discontinuation.

In this interview with Dr. Roy S. Herbst, we discuss the FDA approval of nivolumab for lung cancer as well as other immunotherapies under investigation for the treatment of lung cancer.

A new study identified the molecule known as N1,N12-diacetylspermine as a potential biomarker for early-stage non–small-cell lung cancer.

Differences in failure-to-rescue rates may explain a wide variation in mortality in patients undergoing lung cancer resection at different hospitals, according to a new study.

In this interview, Dr. Sumithra J. Mandrekar talks about umbrella versus basket trials in lung cancer.

New classification guidelines for histologic subtypes of stage I lung adenocarcinoma offer prognostic value, according to a recent study.

Limited resection is not as effective as lobectomy in older patients with early-stage lung cancer, according to a new study.

Six carbonyl compounds in exhaled breath can effectively discriminate between lung cancer patients and healthy patients, says a new study.

Adding tivantinib to erlotinib improved progression-free survival but not overall survival in patients with previously treated non-small-cell lung cancer.

This slide show provides information on the present and future of targeted therapies and immunotherapies based on a report from the IMS Institute for Healthcare Informatics.

Recent progress in lung cancer was a bright spot at the 2015 ASCO Annual Meeting. Several studies were presented that either are practice-changing or will likely lead to practice changes in the future.

The use of CT-guided radiofrequency ablation is well tolerated and effective among patients with inoperable stage IA non-small-cell lung cancer.

Use of post-operative radiotherapy was associated with better overall survival in patients with incompletely resected stage II/III non-small-cell lung cancer.

Large proportions of lung and colorectal cancer patients believe that surgery will cure their cancer, according to results of a new population-based study.

The combination of pemetrexed/cisplatin was superior to gemcitabine/cisplatin in non-squamous NSCLC patients negative for the thymidylate synthase enzyme.

A 39-year-old woman presents with dyspnea and cough. A bronchial mass in found. What is your diagnosis?

A 51-year-old man presents with a lung mass. What is your diagnosis?

Not surprisingly, this was a very popular topic. I’m not sure why the ASCO planners didn’t anticipate this, because I had to wait a few minutes outside the door to even get in. At one point, it was standing room only!